3,204 results on '"Baccarani, Michele"'
Search Results
2. A Review and an Update of European LeukemiaNet Recommendations for the Management of Chronic Myeloid Leukemia
3. INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia
4. Consistency matters : measurement invariance of the EORTC QLQ-C30 questionnaire in patients with hematologic malignancies
5. Why chronic myeloid leukaemia cannot be cured by tyrosine kinase-inhibitors
6. BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS
7. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial
8. Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP
9. Validation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Summary Score in Patients With Hematologic Malignancies
10. High-risk additional chromosomal abnormalities at low blast counts herald death by CML
11. The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia
12. Chronic myeloid leukemia: the concepts of resistance and persistence and the relationship with the BCR-ABL1 transcript type
13. Prognostic factors of chronic myeloid leukaemia
14. In Ph+BCR-ABL1P210+ acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalent
15. Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial
16. The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview
17. Data from c-MYC Oncoprotein Dictates Transcriptional Profiles of ATP-Binding Cassette Transporter Genes in Chronic Myelogenous Leukemia CD34+ Hematopoietic Progenitor Cells
18. Supplementary Figures 1-4, Tables 1-2 from c-MYC Oncoprotein Dictates Transcriptional Profiles of ATP-Binding Cassette Transporter Genes in Chronic Myelogenous Leukemia CD34+ Hematopoietic Progenitor Cells
19. A Review and an Update of European LeukemiaNet Recommendations for the Management of Chronic Myeloid Leukemia
20. Safety Profiles of First-Line TKIs and Managing Adverse Effects
21. Supplementary Methods, Tables 1-7, Figures 1-4 from CDKN2A/B Alterations Impair Prognosis in Adult BCR-ABL1–Positive Acute Lymphoblastic Leukemia Patients
22. Supplementary Tables 1-5 from Gene Expression Analysis of Angioimmunoblastic Lymphoma Indicates Derivation from T Follicular Helper Cells and Vascular Endothelial Growth Factor Deregulation
23. Supplementary File 1 from Gene Expression Analysis of Angioimmunoblastic Lymphoma Indicates Derivation from T Follicular Helper Cells and Vascular Endothelial Growth Factor Deregulation
24. Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series
25. Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients
26. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial
27. Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients
28. Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study
29. Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina
30. Correction: High-risk additional chromosomal abnormalities at low blast counts herald death by CML
31. Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia
32. No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib
33. Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion
34. Psychological well-being and social support in chronic myeloid leukemia patients receiving lifelong targeted therapies
35. Current management of CML patients: Summary of the Italian Consensus Meeting held in Rome, April 11–12, 2013
36. Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitors
37. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)
38. International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24
39. Subcutaneous Omacetaxine Mepesuccinate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With 2 or More Tyrosine Kinase Inhibitors Including Imatinib
40. Tyrosine kinase inhibitors in Ph+ acute lymphoblastic leukaemia: facts and perspectives
41. Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study
42. Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 study
43. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
44. Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia
45. Molecular Monitoring of BCR-ABL Transcripts after Allogeneic Stem Cell Transplantation for Chronic Myeloid Leukemia
46. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
47. Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?
48. A population‐based study of chronic myeloid leukemia patients treated with imatinib in first line
49. Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase
50. A review of the European LeukemiaNet recommendations for the management of CML
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.